Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTAEXS617 in Advanced Solid Tumors
NCT05985655Phase 2Recruiting
- Sponsor
- Exscientia
- Start
- Jul 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of EXS617 in head and neck squamous cell carcinoma (HNSCC), pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 4 more (4 arms), sponsored by Exscientia. Primary endpoints: Treatment Emergent Adverse Events up to 2 years, Dose Limiting Toxicities up to 28 days and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
EXS617
03
Conditions
head and neck squamous cell carcinoma (HNSCC)pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)breast cancerovarian cancer
Beyond the preview
Go deeper on NCT05985655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985655.